Vaxcyte: COO Wassil Jim sold 18,000 shares

What happened

• Wassil Jim, EVP, chief scientific officer and chief operating officer, exercised options and sold shares on Oct 5, 2026. The Form 4 reports an option exercise acquiring 18,000 shares at $5.35 for $96,300, an open-market sale of 18,000 shares at $86.74 for $1,561,320, and an exercise/conversion of a derivative for 18,000 shares reported at $0.00 (disposed).

Key details

• Transaction dates and prices: Oct 5, 2026 — exercised 18,000 shares at $5.35 (acquired) for $96,300; Oct 5, 2026 — sold 18,000 shares at $86.74 (disposed) for $1,561,320; Oct 5, 2026 — exercised/converted derivative 18,000 shares at $0.00 (disposed).
• Shares owned after the transaction: not specified on the Form 4 provided.
• Footnotes: sale effected pursuant to a Rule 10b5-1 trading plan adopted Dec 9, 2025; the stock option is fully vested and exercisable.
• Filing timeliness: the Form 4 does not indicate that the filing was late.

Why it may matter

• The filing shows options were exercised and the acquired shares were sold the same day (cashless exercise).
• A derivative conversion/exercise at $0.00 was reported as disposed on the same date.
• The filing does not show why the insider traded or why the company acted.